IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0221769.html
   My bibliography  Save this article

Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal coverage scheme of Punjab state in India

Author

Listed:
  • Yashika Chugh
  • Radha Krishan Dhiman
  • Madhumita Premkumar
  • Shankar Prinja
  • Gagandeep Singh Grover
  • Pankaj Bahuguna

Abstract

Background: We undertook this study to assess the incremental cost per quality adjusted life year (QALY) gained with the use of pan-genotypic sofosbuvir (SOF) + velpatasvir (VEL) for HCV patients, as compared to the current treatment regimen under the universal free treatment scheme in Punjab state. Methodology: A Markov model depicting natural history of HCV was developed to simulate the progression of disease. Three scenarios were compared: I (Current Regimen)—use of SOF + daclatasvir (DCV) for non-cirrhotic patients and ledipasvir (LDV) or DCV with SOF ± ribavirin (RBV) according to the genotype for cirrhotic patients; II—use of SOF + DCV for non-cirrhotic patients and use of SOF+VEL for compensated cirrhotic patients (with RBV in decompensated cirrhosis patients) and III—use of SOF+VEL for both non-cirrhotic and compensated cirrhotic patients (with RBV in decompensated cirrhosis patients). The lifetime costs, life-years and QALYs were assessed for each scenario, using a societal perspective. All the future costs and health outcomes were discounted at an annual rate of 3%. Finally, the incremental cost per QALY gained was computed for each of scenario II and III, as compared to scenario I and for scenario III as compared to II. In addition, we evaluated the lifetime costs and QALYs among HCV patients for each of scenario I, II and III against the counterfactual of ‘no universal free treatment scheme’ scenario which involves patients purchasing care in routine setting of from public and private sector. Results: Each of the scenarios I, II and III dominate over the no universal free treatment scheme scenario, i.e. have greater QALYs and lesser costs. The use of SOF+VEL only for cirrhotic patients (scenario II) increases QALYs by 0.28 (0.03 to 0.71) per person, and decreases the cost by ₹ 5,946 (₹ 1,198 to ₹ 14,174) per patient, when compared to scenario I. Compared to scenario I, scenario III leads to an increase in QALYs by 0.44 (0.14 to 1.01) per person, and is cost-neutral. While the mean cost difference between scenario III and I is—₹ 2,676 per patient, it ranges from a cost saving of ₹ 14,835 to incurring an extra cost of ₹ 3,456 per patient. For scenario III as compared II, QALYs increase by 0.16 (0.03 to 0.36) per person as well as costs by ₹ 3,086 per patient which ranges from a cost saving of ₹ 1,264 to incurring an extra cost of ₹ 6,344. Shift to scenario II and III increases the program budget by 5.5% and 60% respectively. Conclusion: Overall, the use of SOF+VEL is highly recommended for the treatment of HCV infection. In comparison to the current practice (scenario I), scenario II is a dominant option. Scenario III is cost-effective as compared to scenario II at a threshold of one-time GDP per capita. If budget is an important constraint, velpatasvir should be given to HCV infected cirrhotic patients. However, if no budget constraint, universal use of velpatasvir for HCV treatment is recommended.

Suggested Citation

  • Yashika Chugh & Radha Krishan Dhiman & Madhumita Premkumar & Shankar Prinja & Gagandeep Singh Grover & Pankaj Bahuguna, 2019. "Real-world cost-effectiveness of pan-genotypic Sofosbuvir-Velpatasvir combination versus genotype dependent directly acting anti-viral drugs for treatment of hepatitis C patients in the universal cove," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-24, August.
    • Handle: RePEc:plo:pone00:0221769
    DOI: 10.1371/journal.pone.0221769
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0221769
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0221769&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0221769?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Jamison Pike & Scott D. Grosse, 2018. "Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review," Applied Health Economics and Health Policy, Springer, vol. 16(6), pages 765-778, December.
    2. Paul Revill & Jessica Ochalek & James Lomas & Ryota Nakamura & Beth Woods & Alexandra Rollinger & Marc Suhrcke & Mark Sculpher & Karl Claxton & Peter Berman, 2020. "Cost-Effectiveness Thresholds: Guiding Health Care Spending for Population Health Improvement," World Scientific Book Chapters, in: Paul Revill & Marc Suhrcke & Rodrigo Moreno-Serra & Mark Sculpher (ed.), Global Health Economics Shaping Health Policy in Low- and Middle-Income Countries, chapter 3, pages 75-97, World Scientific Publishing Co. Pte. Ltd..
    3. Shankar Prinja & Akashdeep Chauhan & Blake Angell & Indrani Gupta & Stephen Jan, 2015. "A Systematic Review of the State of Economic Evaluation for Health Care in India," Applied Health Economics and Health Policy, Springer, vol. 13(6), pages 595-613, December.
    4. Rakesh Aggarwal & Qiushi Chen & Amit Goel & Nicole Seguy & Razia Pendse & Turgay Ayer & Jagpreet Chhatwal, 2017. "Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India," PLOS ONE, Public Library of Science, vol. 12(5), pages 1-15, May.
    5. Blake J Angell & Shankar Prinja & Anadi Gupt & Vivekanand Jha & Stephen Jan, 2019. "The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana and the path to universal health coverage in India: Overcoming the challenges of stewardship and governance," PLOS Medicine, Public Library of Science, vol. 16(3), pages 1-6, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Beata Gavurova & Miriama Tarhanicova, 2021. "Methods for Estimating Avoidable Costs of Excessive Alcohol Consumption," IJERPH, MDPI, vol. 18(9), pages 1-25, May.
    2. Manuela De Allegri & Swati Srivastava & Christoph Strupat & Stephan Brenner & Divya Parmar & Diletta Parisi & Caitlin Walsh & Sahil Mahajan & Rupak Neogi & Susanne Ziegler & Sharmishtha Basu & Nishant, 2020. "Mixed and Multi-Methods Protocol to Evaluate Implementation Processes and Early Effects of the Pradhan Mantri Jan Arogya Yojana Scheme in Seven Indian States," IJERPH, MDPI, vol. 17(21), pages 1-15, October.
    3. Błażej Łyszczarz & Karolina Sowa, 2022. "Production losses due to mortality associated with modifiable health risk factors in Poland," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(1), pages 33-45, February.
    4. Yashika Chugh & Pankaj Bahuguna & Aamir Sohail & Kavitha Rajsekar & V. R. Muraleedharan & Shankar Prinja, 2023. "Development of a Health Technology Assessment Quality Appraisal Checklist (HTA-QAC) for India," Applied Health Economics and Health Policy, Springer, vol. 21(1), pages 11-22, January.
    5. Hanly, Paul & Ortega Ortega, Marta & Pearce, Alison & Soerjomataram, Isabelle & Sharp, Linda, 2020. "Advances in the methodological approach to friction period estimation: A European perspective," Social Science & Medicine, Elsevier, vol. 264(C).
    6. Ina Rissanen & Leena Ala-Mursula & Iiro Nerg & Marko Korhonen, 2021. "Adjusted productivity costs of stroke by human capital and friction cost methods: a Northern Finland Birth Cohort 1966 study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(4), pages 531-545, June.
    7. Susanne Mayer & Noemi Kiss & Agata Łaszewska & Judit Simon, 2017. "Costing evidence for health care decision-making in Austria: A systematic review," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-18, August.
    8. Paul Hanly & Marta Ortega Ortega & Alison Pearce & Marianna Camargo Cancela & Isabelle Soerjomataram & Linda Sharp, 2023. "Estimating Global Friction Periods for Economic Evaluation: A Case Study of Selected OECD Member Countries," PharmacoEconomics, Springer, vol. 41(9), pages 1093-1101, September.
    9. Gesine Meyer-Rath & Craig van Rensburg & Bruce Larson & Lise Jamieson & Sydney Rosen, 2017. "Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-9, October.
    10. Peter Lindgren & Sofia Löfvendahl & Gunnar Brådvik & Ola Weiland & Bengt Jönsson, 2022. "Value appropriation in hepatitis C," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 23(6), pages 1059-1070, August.
    11. Jessica Ochalek & Miqdad Asaria & Pei Fen Chuar & James Lomas & Sumit Mazumdar & Karl Claxton, 2019. "Assessing health opportunity costs for the Indian health care systems," Working Papers 161cherp, Centre for Health Economics, University of York.
    12. Anita W M Suijkerbuijk & Albert Jan van Hoek & Jelle Koopsen & Robert A de Man & Marie-Josee J Mangen & Hester E de Melker & Johan J Polder & G Ardine de Wit & Irene K Veldhuijzen, 2018. "Cost-effectiveness of screening for chronic hepatitis B and C among migrant populations in a low endemic country," PLOS ONE, Public Library of Science, vol. 13(11), pages 1-16, November.
    13. Santini, Ziggi Ivan & Thygesen, Lau Caspar & Koyanagi, Ai & Stewart-Brown, Sarah & Meilstrup, Charlotte & Nielsen, Line & Olsen, Kim Rose & Birkjær, Michael & McDaid, David & Koushede, Vibeke & Ekholm, 2022. "Economics of mental wellbeing: a prospective study estimating associated productivity costs due to sickness absence from the workplace in Denmark," LSE Research Online Documents on Economics 116690, London School of Economics and Political Science, LSE Library.
    14. Shankar Prinja & Laura E. Downey & Vijay K. Gauba & Soumya Swaminathan, 2018. "Health Technology Assessment for Policy Making in India: Current Scenario and Way Forward," PharmacoEconomics - Open, Springer, vol. 2(1), pages 1-3, March.
    15. Shankar Prinja & Akashdeep Singh Chauhan & Anup Karan & Gunjeet Kaur & Rajesh Kumar, 2017. "Impact of Publicly Financed Health Insurance Schemes on Healthcare Utilization and Financial Risk Protection in India: A Systematic Review," PLOS ONE, Public Library of Science, vol. 12(2), pages 1-19, February.
    16. Rajesh Chandwani, 2021. "Stakeholders in the Indian Healthcare Sector," Vikalpa: The Journal for Decision Makers, , vol. 46(2), pages 65-70, June.
    17. Juan Oliva-Moreno & Marta Trapero-Bertran & Luz María Peña-Longobardo, 2019. "Gender Differences in Labour Losses Associated with Smoking-Related Mortality," IJERPH, MDPI, vol. 16(19), pages 1-19, September.
    18. Shankar Prinja & Maninder Pal Singh & Kavitha Rajsekar & Oshima Sachin & Praveen Gedam & Anu Nagar & Balram Bhargava, 2021. "Translating Research to Policy: Setting Provider Payment Rates for Strategic Purchasing under India's National Publicly Financed Health Insurance Scheme," Applied Health Economics and Health Policy, Springer, vol. 19(3), pages 353-370, May.
    19. Baudouin Standaert & Christophe Sauboin & Quentin J. Leclerc & Mark P. Connolly, 2021. "Comparing the Analysis and Results of a Modified Social Accounting Matrix Framework with Conventional Methods of Reporting Indirect Non-Medical Costs," PharmacoEconomics, Springer, vol. 39(2), pages 257-269, February.
    20. Nicolas Iragorri & Claire Oliveira & Natalie Fitzgerald & Beverley Essue, 2021. "The Indirect Cost Burden of Cancer Care in Canada: A Systematic Literature Review," Applied Health Economics and Health Policy, Springer, vol. 19(3), pages 325-341, May.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0221769. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.